Abstract
A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component
Journal of clinical oncology, Vol.33(15_suppl), pp.2070-2070
05/20/2015
DOI: 10.1200/jco.2015.33.15_suppl.2070
Abstract
Abstract only
Details
- Title: Subtitle
- A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component
- Creators
- Howard Colman - Huntsman Cancer InstituteFrank Mott - Georgia Regents Medical CenterAlexander I. Spira - Virginia Cancer SpecialistsTheodore S. Johnson - Georgia Regents Medical CenterYousef Zakharia - University of IowaNicholas N. Vahanian - NewLink GeneticsCharles J. Link - NewLink GeneticsEugene Paul Kennedy - NewLink GeneticsRamses F. Sadek - Georgia Regents Medical CenterDavid Munn - Georgia Regents Medical CenterOlivier Rixe - New Mexico Cancer Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.33(15_suppl), pp.2070-2070
- DOI
- 10.1200/jco.2015.33.15_suppl.2070
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2015
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984548262802771
Metrics
2 Record Views